SRSF2 and cyclic hematopoiesis: To further explore the contribution of common genetic variants (minor allele frequency (MAF) ≥ 1%) to CH risk, we performed GWAS in MCPS participants to evaluate both overall CH and driver-gene-specific CH in addition to splicing factor CH (SF3B1 and SRSF2 analyzed in combination).